BridgeMD
New treatment option for Hepatocellular Carcinoma (HCC)
Official title Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant
ClinicalTrials.gov ID: NCT06725121
What this study is testing
What is Atezolizumab & Bevacizumab?
Atezolizumab & Bevacizumab is an investigational medicine, given as a monthly, being studied as a potential treatment for hepatocellular carcinoma (hcc).
Also referred to as AtezoBev, AVASTIN.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to learn if locoregional therapy and immunotherapy can be used together to help patients with hepatocellular carcinoma (HCC) and macrovascular invasion achieve liver transplantation. The main questions it aims to answer are: How many patients will achieve transplant with this treatment strategy?
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Age 18-70
- Weight \> 30 kg
- Child Pugh Turcotte score A5 to B7
- Macrovascular invasion (Vp1-3)
- Total tumour volume \< 350 cm3
You likely can't join if
- Poorly differentiated HCC
- Prior therapy for hepatocellular carcinoma other than liver resection or ablation
- Portal vein tumor thrombus extending beyond main portal vein
- Obesity class III (BMI ≥ 40 kg/m2)
- Contraindications for radiotherapy (Y90 or SBRT) or AtezoBev
See the full eligibility criteria
- Age 18-70
- Weight \> 30 kg
- Child Pugh Turcotte score A5 to B7
- Macrovascular invasion (Vp1-3)
- Total tumour volume \< 350 cm3
- Alpha Fetoprotein \< 5000 ng/mL
- No extrahepatic disease
- No other contraindications to undergo a LT
- Eastern Cooperative Oncology Group (ECOG) score 0-1
- Capable to provide inform consent
- Radiological and histological confirmation of hepatocellular carcinoma
- Poorly differentiated HCC
- Prior therapy for hepatocellular carcinoma other than liver resection or ablation
- Portal vein tumor thrombus extending beyond main portal vein
- Obesity class III (BMI ≥ 40 kg/m2)
- Contraindications for radiotherapy (Y90 or SBRT) or AtezoBev
The study team makes the final eligibility decision.
Where it's taking place
- London, Ontario, Canada
- Toronto, Ontario, Canada
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include London, Ontario, Canada; Toronto, Ontario, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.